Switching older injections to faricimab for wet AMD
Treatments studied
Part of Eyes & vision clinical trials.
This study looks at people with wet AMD who have been getting regular eye injections of either aflibercept or ranibizumab for over a year. The goal is to see what happens when they switch to a newer injection called faricimab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have wet age-related macular degeneration (AMD), a condition that causes abnormal blood vessels to grow under the retina.
- You are currently receiving eye injections of either aflibercept or ranibizumab (these are medicines that help stop the abnormal blood vessels).
- You have been on these injections for more than one year and your injections are needed at least every 12 weeks (i.e., more often than every 12 weeks).
- You do not have severe nearsightedness, certain other eye diseases (like diabetic eye problems, uveitis, or retinal vein occlusion), and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at eye fluid from people with untreated wet AMD to find out why some don't respond well to standard injections. The goal is to improve future treatments.
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
This study tests a biosimilar version of aflibercept (a drug that blocks abnormal blood vessel growth) in people with wet age-related macular degeneration. It aims to see how well the treatment works in real life.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
This trial tests a new injection called faricimab for people with wet age-related macular degeneration (AMD) that hasn't improved enough with standard anti-VEGF shots. The goal is to see if faricimab can reduce retinal fluid and improve vision in patients who still have fluid despite many previous treatments.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.